Home PageHome Page


Test Code
This test is a lab developed test. For further information, see the Compliance Remarks section below.
SynonymsNicotine and Metabolites, Urine, Quantitative; 3-Hydroxycotinine; Anabasine; Cotinine; Nicotine and Cotinine, LC/MS/MS, Urine; Nornicotine; Pain Management
Container TypeLeakproof plastic urine container
Supply Item Number1387
Specimen TypeRandom urine
Preferred Volume4 mL
Emergency Minimum Volume1 mL
Specimen ProcessingTransfer 4 mL with no additives or preservatives urine to a standard PAML aliquot tube.
Store and TransportRefrigerated
StabilityRoom Temp 1 week  Refrigerated 2 weeks  Frozen (-20 °C) 1 month  
Unacceptable ConditionSpecimens exposed to more than 3 freeze/thaw cycles
Reference LaboratoryPAML
CPT Codes80323, (HCPCS G0480)
Interface Order Code83887.Z16
Billing CodeNICMUR
Test ScheduleTue, Thu
Turnaround Time1-5 days
MethodTandem Mass Spectrometry
Reference Ranges
NicotineNon-smoker< 2ng/mL
CotinineNon-smoker< 5ng/mL
3-OH-CotinineNon-smoker< 50ng/mL
NornicotineNon-smoker< 2ng/mL
AnabasineNon-smoker< 10ng/mL
> 100 ng/mL Nicotine indicates use of tobacco products and or nicotine replacement therapy.
> 200 ng/mL Cotinine indicates use of tobacco products and or nicotine replacement therapy. Cotinine is the major metabolite of nicotine.
> 50 ng/mL 3-OH-Cotinine indicates use of tobacco products and or nicotine replacement therapy. 3-OH-Cotinine is a metabolite of Cotinine.
> 30 ng/mL of Nornicotine indicates use of tobacco products and/or nicotine replacement therapy.
> 10 ng/mL Anabasine indicates use of tobacco products. Anabasine is not present in nicotine replacement therapy products such as transdermal patches, gum, nasal sprays and inhalers.
Compliance Remarks This test was developed and its performance characteristics determined by PAML. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. PAML is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
NotesUseful for determination of active or passive nicotine use or for differentiation between nicotine replacement and tobacco use.

Interface Codes
typeorder codetest descriptionresult coderesult descriptionunitsdecimal placesloinc code
o83887.Z16Nicotine and Metabolites, Ur
r83887.Z16Nicotine and Metabolites, Ur83887.Z11Nicotine, Urineng/mL 3854-7
r83887.Z16Nicotine and Metabolites, Ur83887.Z12Cotinine, Urineng/mL 10366-3
r83887.Z16Nicotine and Metabolites, Ur83887.Z133-OH-Cotinine, Urine ng/mL 33916-8
r83887.Z16Nicotine and Metabolites, Ur83887.Z14Nornicotine, Urineng/mL 33917-6
r83887.Z16Nicotine and Metabolites, Ur83887.Z15Anabasine, Urineng/mL 33915-0